ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BioNTech raises $270 million

by Ryan Cross
January 8, 2018 | APPEARED IN VOLUME 96, ISSUE 2

BioNTech, a German company developing mRNA-based therapies, raised a healthy $270 million in its series A funding, led by Redmile Group. The firm’s mRNA therapies include vaccines for infectious diseases, cancer immunotherapy vaccines, and mRNA to make therapeutic proteins in the body. BioNTech has also added small-molecule and CART-cell cancer immunotherapy programs to its pipeline. BioNTech was founded in 2008 by scientists from Johannes Gutenberg University Mainz. Since then it has established pacts with firms such as Bayer Animal Health, Eli Lilly & Co., Genentech, Genmab, and Sanofi.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment